Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
Ontario Institute for Cancer Research · Harvard University · +22 more institutions
Abstract
Treatment with an aromatase inhibitor for 5 years as up-front monotherapy or after tamoxifen therapy is the treatment of choice for hormone-receptor-positive early breast cancer in postmenopausal women. Extending treatment with an aromatase inhibitor to 10 years may further reduce the risk of breast-cancer recurrence.
We conducted a double-blind, placebo-controlled trial to assess the effect of the extended use of letrozole for an additional 5 years. Our primary end point was disease-free survival.
Citation impact
- FWCI
- 83.25
- Percentile
- 100%
- References
- 21
Authors
20- PEPaul E. GossCorresponding
Ontario Institute for Cancer Research, Harvard University, Massachusetts General Hospital
- JNJames N. Ingle
Ontario Institute for Cancer Research, Mayo Clinic in Arizona
- KIKathleen I. Pritchard
Ontario Institute for Cancer Research, Sunnybrook Health Science Centre
- NJNicholas J. Robert
Ontario Institute for Cancer Research, Virginia Cancer Specialists, The US Oncology Network
- HBHyman B. Muss
Ontario Institute for Cancer Research, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center
Topics & keywords
- Letrozole
- Medicine
- Aromatase inhibitor
- Hazard ratio
- Breast cancer
- Internal medicine
- Tamoxifen
- Oncology
- Good health and well-being